STING1 and neoplasm: Wang and colleagues further assumed an inhibition of osteoclastogenesis after treatment of tumor-bearing mice with STING agonists due to a reduced number of osteoclasts in the bone TME, supported by similar observations in vitro with RAW264.7 macrophages or BMDMs (89).